Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-09

AUTHORS

Uwe Schuehly, Surya Ayalasomayajula, Jeppe Buchbjerg, Parasar Pal, Georg Golor, Margaret F. Prescott, Gangadhar Sunkara, Markus Hinder, Thomas H. Langenickel

ABSTRACT

PURPOSE: Sacubitril/valsartan (LCZ696) and nitroglycerin share the second messenger cGMP and lower blood pressure. Given the potential for co-administration of both drugs in patients with heart failure, this study was designed to investigate the potential for a pharmacodynamic drug interaction affecting blood pressure. METHODS: In this double-blind, placebo-controlled, randomised, crossover study, 40 healthy subjects received sacubitril/valsartan 200 mg bid (97/103 mg bid) or placebo for 5 days. Two hours after the morning dose of sacubitril/valsartan or placebo on day 5, subjects received intravenous nitroglycerin infusion at increasing doses up to 40 μg/min or placebo. Serial measurements of blood pressure (BP), heart rate, biomarkers and sacubitril/valsartan pharmacokinetics were conducted. RESULTS: Administration of nitroglycerin alone led to a dose- and time-dependent decrease in supine systolic BP (SBP) and diastolic BP (DBP) which was similar when nitroglycerin was co-administered with sacubitril/valsartan. At the highest dose of nitroglycerin, the mean (95% CI) decrease from baseline of SBP/DBP was 19.54 (- 21.99, - 17.09)/12.38 (- 13.85, - 10.92) mmHg for nitroglycerin alone compared to 22.63 (- 25.06, - 20.21)/12.94 (- 14.38, - 11.49) mmHg when co-administered with sacubitril/valsartan. Co-administration of sacubitril/valsartan and nitroglycerin did not result in further plasma cGMP increase compared to sacubitril/valsartan alone. The co-administration of nitroglycerin and sacubitril/valsartan was safe and well tolerated and did not impact the pharmacokinetics of sacubitril/valsartan. CONCLUSIONS: The results from this study demonstrate no pharmacodynamic drug interaction between nitroglycerin and sacubitril/valsartan in healthy subjects, suggesting that no change of dose selection and escalation recommendations or clinical monitoring during nitroglycerin administration is required. More... »

PAGES

1121-1130

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00228-018-2509-2

DOI

http://dx.doi.org/10.1007/s00228-018-2509-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105307487

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29974143


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schuehly", 
        "givenName": "Uwe", 
        "id": "sg:person.011511313677.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011511313677.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Translational Medicine, Novartis Institutes for Biomedical Research, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ayalasomayajula", 
        "givenName": "Surya", 
        "id": "sg:person.0614511542.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614511542.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buchbjerg", 
        "givenName": "Jeppe", 
        "id": "sg:person.011535202231.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011535202231.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Biostatistical Sciences, Novartis Healthcare Pvt. Ltd., Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pal", 
        "givenName": "Parasar", 
        "id": "sg:person.0615427741.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615427741.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "PARAXEL GmbH, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Golor", 
        "givenName": "Georg", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Novartis Pharma AG, East Hannover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Prescott", 
        "givenName": "Margaret F.", 
        "id": "sg:person.01057745102.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057745102.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Translational Medicine, Novartis Institutes for Biomedical Research, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sunkara", 
        "givenName": "Gangadhar", 
        "id": "sg:person.01045560271.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045560271.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hinder", 
        "givenName": "Markus", 
        "id": "sg:person.0634570605.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634570605.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Langenickel", 
        "givenName": "Thomas H.", 
        "id": "sg:person.01355773351.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355773351.48"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0002-9149(99)00044-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000433733"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/13543784.2013.797962", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002501228"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/hc1002.105186", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003861776"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000258532.07418.fa", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005416490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.hyp.0000258532.07418.fa", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005416490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199908193410806", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006241217"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m000786200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012906543"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/ajpcell.00590.2002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013099756"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.0710387105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015672973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.88.1.29", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016509681"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1378/chest.79.1.69", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018410831"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2004.02243.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019934674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9149(99)80750-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025206844"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehv142", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026804571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0091270009343932", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027199444"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199203000-00011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036865435"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00004872-199203000-00011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036865435"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/pr.110.002907", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037344275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehs262", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037810847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/cir.0000000000000134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038340217"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/cir.0000000000000134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038340217"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.jhh.1001683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039527092", 
          "https://doi.org/10.1038/sj.jhh.1001683"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.jhh.1001683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039527092", 
          "https://doi.org/10.1038/sj.jhh.1001683"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.jhh.1001683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039527092", 
          "https://doi.org/10.1038/sj.jhh.1001683"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.107.183885", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046513676"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/1755-5922.12183", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050534622"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.115.018622", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063344193"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.115.018622", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063344193"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/ajpheart.2001.281.1.h146", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074834869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/jappl.2002.92.1.257", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074963331"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/153537020523000403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077029099"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/153537020523000403", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1077029099"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-09", 
    "datePublishedReg": "2018-09-01", 
    "description": "PURPOSE: Sacubitril/valsartan (LCZ696) and nitroglycerin share the second messenger cGMP and lower blood pressure. Given the potential for co-administration of both drugs in patients with heart failure, this study was designed to investigate the potential for a pharmacodynamic drug interaction affecting blood pressure.\nMETHODS: In this double-blind, placebo-controlled, randomised, crossover study, 40 healthy subjects received sacubitril/valsartan 200\u00a0mg bid (97/103\u00a0mg bid) or placebo for 5\u00a0days. Two hours after the morning dose of sacubitril/valsartan or placebo on day 5, subjects received intravenous nitroglycerin infusion at increasing doses up to 40\u00a0\u03bcg/min or placebo. Serial measurements of blood pressure (BP), heart rate, biomarkers and sacubitril/valsartan pharmacokinetics were conducted.\nRESULTS: Administration of nitroglycerin alone led to a dose- and time-dependent decrease in supine systolic BP (SBP) and diastolic BP (DBP) which was similar when nitroglycerin was co-administered with sacubitril/valsartan. At the highest dose of nitroglycerin, the mean (95% CI) decrease from baseline of SBP/DBP was 19.54 (-\u200921.99, -\u200917.09)/12.38 (-\u200913.85, -\u200910.92) mmHg for nitroglycerin alone compared to 22.63 (-\u200925.06, -\u200920.21)/12.94 (-\u200914.38, -\u200911.49) mmHg when co-administered with sacubitril/valsartan. Co-administration of sacubitril/valsartan and nitroglycerin did not result in further plasma cGMP increase compared to sacubitril/valsartan alone. The co-administration of nitroglycerin and sacubitril/valsartan was safe and well tolerated and did not impact the pharmacokinetics of sacubitril/valsartan.\nCONCLUSIONS: The results from this study demonstrate no pharmacodynamic drug interaction between nitroglycerin and sacubitril/valsartan in healthy subjects, suggesting that no change of dose selection and escalation recommendations or clinical monitoring during nitroglycerin administration is required.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00228-018-2509-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "74"
      }
    ], 
    "name": "Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects", 
    "pagination": "1121-1130", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "92a1556612fd4a34433c7aca318431570d508f8c741e70488cbb3a2a4927fb79"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29974143"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "1256165"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00228-018-2509-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105307487"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00228-018-2509-2", 
      "https://app.dimensions.ai/details/publication/pub.1105307487"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000604.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs00228-018-2509-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2509-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2509-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2509-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2509-2'


 

This table displays all metadata directly associated to this object as RDF triples.

210 TRIPLES      21 PREDICATES      54 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00228-018-2509-2 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 schema:author Nedea36706cd14842870ba9ced4ff1998
4 schema:citation sg:pub.10.1038/sj.jhh.1001683
5 https://doi.org/10.1016/s0002-9149(99)00044-2
6 https://doi.org/10.1016/s0002-9149(99)80750-4
7 https://doi.org/10.1056/nejm199908193410806
8 https://doi.org/10.1073/pnas.0710387105
9 https://doi.org/10.1074/jbc.m000786200
10 https://doi.org/10.1093/eurheartj/ehs262
11 https://doi.org/10.1093/eurheartj/ehv142
12 https://doi.org/10.1097/00004872-199203000-00011
13 https://doi.org/10.1111/1755-5922.12183
14 https://doi.org/10.1111/j.1365-2125.2004.02243.x
15 https://doi.org/10.1124/pr.110.002907
16 https://doi.org/10.1152/ajpcell.00590.2002
17 https://doi.org/10.1152/ajpheart.2001.281.1.h146
18 https://doi.org/10.1152/jappl.2002.92.1.257
19 https://doi.org/10.1161/01.cir.88.1.29
20 https://doi.org/10.1161/01.hyp.0000258532.07418.fa
21 https://doi.org/10.1161/cir.0000000000000134
22 https://doi.org/10.1161/circulationaha.107.183885
23 https://doi.org/10.1161/circulationaha.115.018622
24 https://doi.org/10.1161/hc1002.105186
25 https://doi.org/10.1177/0091270009343932
26 https://doi.org/10.1177/153537020523000403
27 https://doi.org/10.1378/chest.79.1.69
28 https://doi.org/10.1517/13543784.2013.797962
29 schema:datePublished 2018-09
30 schema:datePublishedReg 2018-09-01
31 schema:description PURPOSE: Sacubitril/valsartan (LCZ696) and nitroglycerin share the second messenger cGMP and lower blood pressure. Given the potential for co-administration of both drugs in patients with heart failure, this study was designed to investigate the potential for a pharmacodynamic drug interaction affecting blood pressure. METHODS: In this double-blind, placebo-controlled, randomised, crossover study, 40 healthy subjects received sacubitril/valsartan 200 mg bid (97/103 mg bid) or placebo for 5 days. Two hours after the morning dose of sacubitril/valsartan or placebo on day 5, subjects received intravenous nitroglycerin infusion at increasing doses up to 40 μg/min or placebo. Serial measurements of blood pressure (BP), heart rate, biomarkers and sacubitril/valsartan pharmacokinetics were conducted. RESULTS: Administration of nitroglycerin alone led to a dose- and time-dependent decrease in supine systolic BP (SBP) and diastolic BP (DBP) which was similar when nitroglycerin was co-administered with sacubitril/valsartan. At the highest dose of nitroglycerin, the mean (95% CI) decrease from baseline of SBP/DBP was 19.54 (- 21.99, - 17.09)/12.38 (- 13.85, - 10.92) mmHg for nitroglycerin alone compared to 22.63 (- 25.06, - 20.21)/12.94 (- 14.38, - 11.49) mmHg when co-administered with sacubitril/valsartan. Co-administration of sacubitril/valsartan and nitroglycerin did not result in further plasma cGMP increase compared to sacubitril/valsartan alone. The co-administration of nitroglycerin and sacubitril/valsartan was safe and well tolerated and did not impact the pharmacokinetics of sacubitril/valsartan. CONCLUSIONS: The results from this study demonstrate no pharmacodynamic drug interaction between nitroglycerin and sacubitril/valsartan in healthy subjects, suggesting that no change of dose selection and escalation recommendations or clinical monitoring during nitroglycerin administration is required.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf N11b59066e248409893c99d1a39c89e3f
36 Ne18acf43a6e948589ae414f9cd7eb2a8
37 sg:journal.1054337
38 schema:name Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects
39 schema:pagination 1121-1130
40 schema:productId N13d0202378ee4020ad24136ab9f5ff73
41 N28dd45d1e54f4473b3b0abad100f3cf2
42 N3ed3afc959fb47d8aa68ff747a811dbb
43 Nb7d46a53f2494324b1d3e0601594542c
44 Nbad0ff6e74074455902565830e9fb6f3
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105307487
46 https://doi.org/10.1007/s00228-018-2509-2
47 schema:sdDatePublished 2019-04-10T21:00
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher Nff34cd3519824adc9780337677b02d33
50 schema:url http://link.springer.com/10.1007%2Fs00228-018-2509-2
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N005595272fd14f2cbce952ead415930b rdf:first sg:person.0614511542.56
55 rdf:rest N2d6d98ee0b82456b916211946ee22e56
56 N11b59066e248409893c99d1a39c89e3f schema:issueNumber 9
57 rdf:type schema:PublicationIssue
58 N13d0202378ee4020ad24136ab9f5ff73 schema:name doi
59 schema:value 10.1007/s00228-018-2509-2
60 rdf:type schema:PropertyValue
61 N28dd45d1e54f4473b3b0abad100f3cf2 schema:name pubmed_id
62 schema:value 29974143
63 rdf:type schema:PropertyValue
64 N2d6d98ee0b82456b916211946ee22e56 rdf:first sg:person.011535202231.38
65 rdf:rest Na849850d1b1d4826b42a101fa8f07f4e
66 N380519e03fa34035b3245a00e3644374 rdf:first sg:person.01057745102.19
67 rdf:rest Nab12570013d64847a66cf4c2055d257a
68 N3ed3afc959fb47d8aa68ff747a811dbb schema:name nlm_unique_id
69 schema:value 1256165
70 rdf:type schema:PropertyValue
71 N8540ff5229474a57b4830d48cc2fcc5e schema:name Novartis Pharma AG, East Hannover, NJ, USA
72 rdf:type schema:Organization
73 N8cfd5b62c3594e558fe463d3af8049be rdf:first sg:person.0634570605.99
74 rdf:rest N9190a93d7df94e86b03892eecb3cf0a3
75 N9190a93d7df94e86b03892eecb3cf0a3 rdf:first sg:person.01355773351.48
76 rdf:rest rdf:nil
77 Na46e810e36f04b2980b6ec18c6bb5905 schema:name PARAXEL GmbH, Berlin, Germany
78 rdf:type schema:Organization
79 Na849850d1b1d4826b42a101fa8f07f4e rdf:first sg:person.0615427741.32
80 rdf:rest Nb3b924d34e3d4b7fa22a132fd4989311
81 Nab12570013d64847a66cf4c2055d257a rdf:first sg:person.01045560271.81
82 rdf:rest N8cfd5b62c3594e558fe463d3af8049be
83 Nb3b924d34e3d4b7fa22a132fd4989311 rdf:first Nf0644a98554d4779934325ef81dd38fa
84 rdf:rest N380519e03fa34035b3245a00e3644374
85 Nb7d46a53f2494324b1d3e0601594542c schema:name readcube_id
86 schema:value 92a1556612fd4a34433c7aca318431570d508f8c741e70488cbb3a2a4927fb79
87 rdf:type schema:PropertyValue
88 Nbad0ff6e74074455902565830e9fb6f3 schema:name dimensions_id
89 schema:value pub.1105307487
90 rdf:type schema:PropertyValue
91 Ne18acf43a6e948589ae414f9cd7eb2a8 schema:volumeNumber 74
92 rdf:type schema:PublicationVolume
93 Nedea36706cd14842870ba9ced4ff1998 rdf:first sg:person.011511313677.40
94 rdf:rest N005595272fd14f2cbce952ead415930b
95 Nf0644a98554d4779934325ef81dd38fa schema:affiliation Na46e810e36f04b2980b6ec18c6bb5905
96 schema:familyName Golor
97 schema:givenName Georg
98 rdf:type schema:Person
99 Nff34cd3519824adc9780337677b02d33 schema:name Springer Nature - SN SciGraph project
100 rdf:type schema:Organization
101 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
102 schema:name Medical and Health Sciences
103 rdf:type schema:DefinedTerm
104 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
105 schema:name Cardiorespiratory Medicine and Haematology
106 rdf:type schema:DefinedTerm
107 sg:journal.1054337 schema:issn 0031-6970
108 1432-1041
109 schema:name European Journal of Clinical Pharmacology
110 rdf:type schema:Periodical
111 sg:person.01045560271.81 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
112 schema:familyName Sunkara
113 schema:givenName Gangadhar
114 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045560271.81
115 rdf:type schema:Person
116 sg:person.01057745102.19 schema:affiliation N8540ff5229474a57b4830d48cc2fcc5e
117 schema:familyName Prescott
118 schema:givenName Margaret F.
119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01057745102.19
120 rdf:type schema:Person
121 sg:person.011511313677.40 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
122 schema:familyName Schuehly
123 schema:givenName Uwe
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011511313677.40
125 rdf:type schema:Person
126 sg:person.011535202231.38 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
127 schema:familyName Buchbjerg
128 schema:givenName Jeppe
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011535202231.38
130 rdf:type schema:Person
131 sg:person.01355773351.48 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
132 schema:familyName Langenickel
133 schema:givenName Thomas H.
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355773351.48
135 rdf:type schema:Person
136 sg:person.0614511542.56 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
137 schema:familyName Ayalasomayajula
138 schema:givenName Surya
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614511542.56
140 rdf:type schema:Person
141 sg:person.0615427741.32 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
142 schema:familyName Pal
143 schema:givenName Parasar
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615427741.32
145 rdf:type schema:Person
146 sg:person.0634570605.99 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
147 schema:familyName Hinder
148 schema:givenName Markus
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634570605.99
150 rdf:type schema:Person
151 sg:pub.10.1038/sj.jhh.1001683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039527092
152 https://doi.org/10.1038/sj.jhh.1001683
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1016/s0002-9149(99)00044-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000433733
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1016/s0002-9149(99)80750-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025206844
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1056/nejm199908193410806 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006241217
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1073/pnas.0710387105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015672973
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1074/jbc.m000786200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012906543
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1093/eurheartj/ehs262 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037810847
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1093/eurheartj/ehv142 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026804571
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1097/00004872-199203000-00011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036865435
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1111/1755-5922.12183 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050534622
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1111/j.1365-2125.2004.02243.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019934674
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1124/pr.110.002907 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037344275
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1152/ajpcell.00590.2002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013099756
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1152/ajpheart.2001.281.1.h146 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074834869
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1152/jappl.2002.92.1.257 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074963331
181 rdf:type schema:CreativeWork
182 https://doi.org/10.1161/01.cir.88.1.29 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016509681
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1161/01.hyp.0000258532.07418.fa schema:sameAs https://app.dimensions.ai/details/publication/pub.1005416490
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1161/cir.0000000000000134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038340217
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1161/circulationaha.107.183885 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046513676
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1161/circulationaha.115.018622 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063344193
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1161/hc1002.105186 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003861776
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1177/0091270009343932 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027199444
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1177/153537020523000403 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077029099
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1378/chest.79.1.69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018410831
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1517/13543784.2013.797962 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002501228
201 rdf:type schema:CreativeWork
202 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
203 schema:name Translational Medicine, Novartis Institutes for Biomedical Research, East Hanover, NJ, USA
204 rdf:type schema:Organization
205 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
206 schema:name Translational Medicine, Novartis Institutes for Biomedical Research, Basel, Switzerland
207 rdf:type schema:Organization
208 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
209 schema:name Biostatistical Sciences, Novartis Healthcare Pvt. Ltd., Hyderabad, India
210 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...